{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:48:28Z","timestamp":1787629708022,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-026-10603-9","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T07:33:01Z","timestamp":1773819181000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evolving strategies in obstructive hypertrophic cardiomyopathy: myosin inhibitors as monotherapy compared with beta-blockers"],"prefix":"10.1007","volume":"31","author":[{"given":"Avishay","family":"Grupper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron L.","family":"Sverdlov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baljash S.","family":"Cheema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Nasrollahizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaveh","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"10603_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jacc.2014.05.003","volume":"64","author":"BJ Maron","year":"2014","unstructured":"Maron BJ, Ommen SR, Semsarian C et al (2014) Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol 64:83\u201399","journal-title":"J Am Coll Cardiol"},{"key":"10603_CR2","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"PM Elliott","year":"2023","unstructured":"Elliott PM, Charron P, Arbustini E et al (2023) 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J 44:3503\u20133626","journal-title":"Eur Heart J"},{"key":"10603_CR3","doi-asserted-by":"publisher","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","volume":"149","author":"SR Ommen","year":"2024","unstructured":"Ommen SR, Ho CY, Asif IM et al (2024) 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation 149:e1239\u2013e1311","journal-title":"Circulation"},{"key":"10603_CR4","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1056\/NEJM199703133361107","volume":"336:11","author":"P Spirito","year":"1997","unstructured":"Spirito P, Seidman CE, McKenna WJ et al (1997) The management of hypertrophic cardiomyopathy. N Engl J Med 336:11:775\u2013785","journal-title":"N Engl J Med"},{"key":"10603_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1126\/science.aad3456","volume":"351","author":"EM Green","year":"2016","unstructured":"Green EM, Wakimoto H, Anderson RL et al (2016) A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science 351:617\u2013621","journal-title":"Science"},{"key":"10603_CR6","doi-asserted-by":"publisher","first-page":"741","DOI":"10.7326\/M18-3016","volume":"170","author":"SB Heitner","year":"2019","unstructured":"Heitner SB, Jacoby D, Lester SJ et al (2019) Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial (PIONEER-HCM). Ann Intern Med 170:741\u2013748","journal-title":"Ann Intern Med"},{"key":"10603_CR7","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R et al (2020) Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 396:759\u2013769","journal-title":"Lancet"},{"key":"10603_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","volume":"80","author":"MY Desai","year":"2022","unstructured":"Desai MY, Owens A, Geske JB et al (2022) Myosin Inhibition in Patients with Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy (VALOR-HCM). J Am Coll Cardiol 80:95\u2013108","journal-title":"J Am Coll Cardiol"},{"key":"10603_CR9","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","volume":"390","author":"MS Maron","year":"2024","unstructured":"Maron MS, Masri A, Nassif ME et al (2024) Aficamten for symptomatic obstructive hypertrophic cardiomyopathy (SEQUOIA-HCM). N Engl J Med 390:1849\u20131861","journal-title":"N Engl J Med"},{"key":"10603_CR10","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1056\/NEJMoa2504654","volume":"393","author":"P Garcia-Pavia","year":"2025","unstructured":"Garcia-Pavia P, Maron MS, Masri A et al Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy (MAPLE-HCM). N Engl J Med (2025) ;393:949\u2013960","journal-title":"N Engl J Med"},{"key":"10603_CR11","doi-asserted-by":"publisher","first-page":"e003460","DOI":"10.1136\/openhrt-2025-003460","volume":"12","author":"AJ Smith","year":"2025","unstructured":"Smith AJ, Cromie AMM, Bowles L et al (2025) Beta blockers and hypertrophic obstructive cardiomyopathy: a systematic review and meta-analysis. Open Heart 12:e003460. https:\/\/doi.org\/10.1136\/openhrt-2025-003460","journal-title":"Open Heart"},{"key":"10603_CR12","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1093\/eurheartj\/ehs150","volume":"33","author":"R Spoladore","year":"2012","unstructured":"Spoladore R, Maron MS, D\u2019Amato R et al (2012) Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. Eur Heart J 33:1724\u20131733","journal-title":"Eur Heart J"},{"key":"10603_CR13","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.jacc.2022.02.021","volume":"79","author":"A Borlaug Barry","year":"2022","unstructured":"Borlaug Barry A, Omote K (2022) Beta-Blockers and Exercise Hemodynamics in Hypertrophic Cardiomyopathy. JACC 79:1576\u20131578","journal-title":"JACC"},{"key":"10603_CR14","first-page":"889","volume":"82","author":"C Palandri","year":"2022","unstructured":"Palandri C, Santini L, Argir\u00f2 A et al (2022) Pharmacol Manage Hypertrophic Cardiomyopathy: Bench Bedside Drugs 82:889\u2013912","journal-title":"Pharmacol Manage Hypertrophic Cardiomyopathy: Bench Bedside Drugs"},{"key":"10603_CR15","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1016\/j.jacc.2021.07.065","volume":"78","author":"AM Dybro","year":"2021","unstructured":"Dybro AM, Rasmussen TB, Nielsen RR et al (2021) Randomized Trial of Metoprolol in Patients with Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol 78:2505\u20132517","journal-title":"J Am Coll Cardiol"},{"key":"10603_CR16","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.jacc.2022.02.024","volume":"79","author":"AM Dybro","year":"2022","unstructured":"Dybro AM et al (2022) Effects of Metoprolol on Exercise Hemodynamics in Patients with Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol 79:1565\u20131575","journal-title":"J Am Coll Cardiol"},{"key":"10603_CR17","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1159\/000175883","volume":"82","author":"M Tendera","year":"1993","unstructured":"Tendera M, Wycisk A, Schneeweiss A et al (1993) Effect of sotalol on arrhythmias and exercise tolerance in patients with hypertrophic cardiomyopathy. Cardiology 82:335\u2013342","journal-title":"Cardiology"},{"key":"10603_CR18","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1751-7176.2009.00251.x","volume":"12","author":"F Aslam","year":"2010","unstructured":"Aslam F, Haque A, Foody J et al (2010) The frequency and functional impact of overlapping hypertension on hypertrophic cardiomyopathy: a single-center experience. J Clin Hypertens (Greenwich) 12:240\u2013245","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10603_CR19","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.117.029267","volume":"136","author":"EJ Rowin","year":"2017","unstructured":"Rowin EJ, Hausvater A, Link MS et al (2017) Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation 136:2420\u20132436","journal-title":"Circulation"},{"key":"10603_CR20","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1093\/eurheartj\/ehx189","volume":"38","author":"S Goland","year":"2017","unstructured":"Goland S, van Hagen IM, Elbaz-Greener G et al (2017) Pregnancy in women with hypertrophic cardiomyopathy: data from the European Society of Cardiology initiated Registry of Pregnancy and Cardiac disease (ROPAC). Eur Heart J 38:2683\u20132690","journal-title":"Eur Heart J"},{"key":"10603_CR21","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1161\/CIRCHEARTFAILURE.112.000122","volume":"6","author":"MV Sherrid","year":"2013","unstructured":"Sherrid MV, Shetty A, Winson G et al (2013) Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with \u03b2-blockade or verapamil. Circ Heart Fail 6:694\u2013702","journal-title":"Circ Heart Fail"},{"key":"10603_CR22","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jchf.2023.04.018","volume":"11","author":"B Ostrominski","year":"2023","unstructured":"Ostrominski B et al (2023) Cardiac myosin inhibition in hypertrophic cardiomyopathy. JACC Heart Fail 11:456\u2013467","journal-title":"JACC Heart Fail"},{"key":"10603_CR23","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","volume":"121","author":"AJ Marian","year":"2017","unstructured":"Marian AJ, Braunwald E (2017) Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 121:749\u2013770","journal-title":"Circ Res"},{"key":"10603_CR24","doi-asserted-by":"publisher","unstructured":"Garcia-Pavia P, Oreziak A, Masri A et al (2024) Long-term safety and efficacy of mavacamten in obstructive hypertrophic cardiomyopathy: up to 3.5-year follow-up results of the EXPLORER cohort of MAVA-Long-Term Extension study. Eur Heart J 45. https:\/\/doi.org\/10.1093\/eurheartj\/ehae666","DOI":"10.1093\/eurheartj\/ehae666"},{"key":"10603_CR25","doi-asserted-by":"publisher","first-page":"16279","DOI":"10.1021\/acs.jmedchem.1c01290","volume":"64","author":"C Chuang","year":"2021","unstructured":"Chuang C et al (2021) Discovery of aficamten: a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy. J Med Chem 64:16279\u201316296","journal-title":"J Med Chem"},{"key":"10603_CR26","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/ejhf.2737","volume":"25","author":"MT Wheeler","year":"2023","unstructured":"Wheeler MT, Jacoby D, Elliott PM et al (2023) Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy. Eur J Heart Fail 25:260\u2013270","journal-title":"Eur J Heart Fail"},{"key":"10603_CR27","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1016\/j.jacc.2024.09.002","volume":"84","author":"A Masri","year":"2024","unstructured":"Masri A, Choudhury L, Barriales-Villa R et al (2024) Standard-of-Care Medication Withdrawal in Patients with Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM. J Am Coll Cardiol 84:1839\u20131849","journal-title":"J Am Coll Cardiol"},{"key":"10603_CR28","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/0002-9149(91)90651-Z","volume":"68","author":"DM Gilligan","year":"1991","unstructured":"Gilligan DM, Chan WL, Stewart R et al (1991) Adrenergic hypersensitivity after beta-blocker withdrawal in hypertrophic cardiomyopathy. Am J Cardiol 68:766\u2013772","journal-title":"Am J Cardiol"},{"key":"10603_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.08.022","author":"SM Hegde","year":"2025","unstructured":"Hegde SM, Wang X, Garcia-Pavia P et al (2025) Effect of Aficamten Compared with Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM. J Am Coll Cardiol. https:\/\/doi.org\/10.1016\/j.jacc.2025.08.022","journal-title":"J Am Coll Cardiol"},{"key":"10603_CR30","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1161\/CIRCULATIONAHA.123.065017","volume":"148","author":"K Seo","year":"2023","unstructured":"Seo K, Yamamoto Y, Kirillova A et al (2023) Improved Cardiac Performance and Decreased Arrhythmia in Hypertrophic Cardiomyopathy with Non\u2013\u03b2-Blocking R-Enantiomer Carvedilol. Circulation 148:1691\u20131704","journal-title":"Circulation"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10603-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-026-10603-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10603-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:23:11Z","timestamp":1781641391000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-026-10603-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10603"],"URL":"https:\/\/doi.org\/10.1007\/s10741-026-10603-9","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"1 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}